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Abstract
Background: Colorectal cancer (CRC) risk is partly conferred by common, low-penetrance single nucleotide polymorphisms
(SNPs). We hypothesized that these SNPs are associated with outcomes in metastatic CRC.
Methods: Six candidate SNPs from 8q24, 10p14, 15q13, 18q21 were investigated for their association with response rate
(RR), time to progression (TTP) and overall survival (OS) among 524 patients treated on a phase III clinical trial of first-line
chemotherapy for metastatic CRC.
Results: rs10795668 was weakly associated with TTP (p = 0.02), but not RR or OS. No other SNPs carried statistically
significant HRs for any of the primary outcomes (RR, TTP or OS).
Conclusion: Common low-penetrance CRC risk SNPs were not associated with outcomes among patients with metastatic
CRC.
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Introduction
The survival of patients with metastatic colorectal cancer is
improving, with more than half of patients enrolled in recent phase
III trials now living more than two years.[1] Despite this improved
prognosis, patient outcomes remain heterogeneous. This hetero-
geneity is increasingly recognized as resulting from distinct
molecular subtypes of colorectal cancers,[2] which in turn is
influenced by the molecular pathway of carcinogenesis through
which cancer develops in individuals.[3] For example the
prognosis of patients whose cancers develop through the
chromosomal instability pathway differs from those who develop
colorectal cancer through germline loss of mismatch repair
enzymes, which differs from the poor prognosis of patients with
cancers characterized by the CpG island methylator phenotype
and BRAF V600E mutation.[4,5]
Genome-wide association studies (GWAS) have identified a
number of loci that increase the risk of developing colorectal
cancer. Single nucleotide polymorphisms (SNPs) at these loci,
including 8q24, 10p14, 15q13, and 18q21, each confer a small
independent increase in the risk of developing colorectal cancer.
[6,7,8,9,10,11,12,13] Given the emerging understanding that the
underlying molecular pathway of colorectal carcinogenesis influ-
ences prognosis of patients with invasive cancer, one or more of
these common ‘‘risk’’ SNPs might be expected to be associated
with outcomes of patients with invasive cancer. To examine
whether these common low penetrance risk alleles might influence
the outcomes of patients with metastatic colorectal cancer, we
evaluated the association between candidate risk SNPS and
clinical outcomes as measured by radiographic response rate (RR),
time to progression (TTP), and overall survival (OS) among




Germline DNA was available for 524 of the 1694 patients
enrolled in North Central Cancer Treatment Group Trial N9741
(registered with ClinicalTrials.gov, NCT00003594), a randomized
trial of irinotecan, oxaliplatin and 5-fluoruracil combinations for
previously untreated metastatic colorectal cancer.[14] Patients
with blood drawn for DNA analysis appeared to be representative
of the enrolled population based upon demographic and known
prognostic factors.[15] Patients had a median age of 61 years, 95%
had an ECOG performance status of 0–1, 86% were White, 8%
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Black, and 4% were Hispanic (Table 1). The parent study,
NCCTG N9741 was approved by the institutional review board at
all participating centers prior to patient enrollment. All patients
gave written informed consent prior to participation. This
secondary analysis of stored specimens and de-identified data
was approved by the University of North Carolina IRB (07-0843).
SNP selection
Six candidate SNPs were selected from known common, low
penetrance colorectal cancer susceptibility loci identified in early
GWAS [8–12] or previously reported to be associated with clinical
outcomes in patients with established colorectal cancer. Selected
SNPs were in minimal linkage disequilibrium with each other to
avoid redundancy. All samples were genotyped for each of the
candidate SNPs using TaqMan allelic discrimination assays
(Applied Biosystems, Foster City, CA, USA) as previously
described.[16] Genotyping was performed blinded fashion to
clinical data.
Statistical analysis
The genotype distribution at each locus was examined for
deviation from Hardy-Weinberg equilibrium (HWE), stratified by
race; none of the SNPs violated the HWE assumption. The
distribution of each SNP was evaluated descriptively across key
covariates, with no difference in genotype according to age, sex,
performance status, or treatment arm. Univariate and multivariate
analyses of each individual SNP were then performed to evaluate
the association of genotype with response rate (RR), time to
progression (TTP) and overall survival (OS). Multivariate models
were adjusted for covariates known to affect these primary
outcomes in N9741,[17] including age, sex, race, performance
status and assigned treatment arm. Given the post hoc nature of
this analysis and the multiple SNPs and endpoints assessed, any
statistically significant results were to be considered hypothesis
generating and to require validation in an independent cohort.
Results
Among 524 patients enrolled to N9741, there was no significant
deviation from Hardy-Weinberg equilibrium for any of the six
candidate SNPs, (Table 2) suggesting that while these SNPs are
associated with risk of developing colorectal cancer, they may not
modify the risk of developing metastatic disease. The six SNPs
were investigated for their effects on response rate, time to
progression and overall survival. When accounting for multiple
testing, there was no association with any SNPs and outcomes of
patients with metastatic colorectal cancer (Table 2). The only
borderline association was between rs10795668 (at locus 10p14)
and TTP. Individuals who were homozygous for the minor allele
at rs10795668 (A/A), when compared with individuals who were
homozygous for the reference allele (G/G), had a shorter time to
progression with an adjusted hazard ratio of 1.43 (95% CI: 1.02–
1.99, p = 0.02). No association was seen between this genotype and
response rate or overall survival. No other SNPs had a statistically
significant association with any of the outcomes of interest (RR,
TTP or OS).
Discussion
GWAS have identified common genetic variants at multiple loci
that increase the risk of developing colorectal cancer. As the
underlying molecular pathway of colorectal carcinogenesis influ-
ences prognosis of patients with invasive cancer, we used a
candidate gene approach to evaluate whether these newly
identified risk genotypes might also affect the course of disease
following the diagnosis of metastatic colorectal cancer. We found
no association between evaluated polymorphisms and clinical
outcome of metastatic colorectal cancer.
While these SNPs have been previously well-validated as
markers of colorectal cancer risk,[6,7,9,10,12,13],[18] the few
prior studies have reported variable associations between these low
penetrance susceptibility SNPs and colorectal cancer outcomes. In
an evaluation of CRC patients of any stage treated at two Chinese
hospitals, patients with the risk allele of rs10795668 had a reduced
risk of colorectal cancer recurrence, but not overall survival; and
the risk allele for rs4779584 was associated with a reduced rate of
death.[19] An evaluation of twenty-six SNPs at GWAS-identified
CRC susceptibility loci in newly diagnosed stage II and III CRC
patients treated with adjuvant fluorouracil-based chemotherapy at
MD Anderson found significant associations between multiple
SNPs and recurrence (rs10749971, rs961253, rs355527) and
survival (rs961253, rs355527, rs4464148, rs6983267,
rs10505477).[20] In contrast, two observational cohort studies of
colorectal cancer patients failed to find an association between any
of these previously cited variants and colorectal cancer outcomes
(with the exception of rs10749971 which was not evaluated in
either study). [16,21] One of these, an analysis of incident
colorectal cancer cases from North Carolina enrolled in the
CanCORS cohort study, found no CRC susceptibility SNP was
associated with clinical outcome.[16] The other reported only the
minor allele of rs4939827 to be associated with a slight increased
risk of death from any stage CRC following diagnosis. [21] A
recent study of women with incident colorectal cancer in the
Seattle-Puget Sound Cancer Surveillance system, found an
association between rs4939827 and rs4464148 and colorectal
cancer survival. [22]
The failure of the majority of these SNPs to be validated
suggests many of the reported associations are likely chance
findings identified in the setting of hypothesis-generating exami-
nations of multiple candidate SNPs. Heterogeneity in patients,
cancer stage, and cancer treatment across genotypes may also
have confounded the ability of these prior studies to find any small
associations. Though the sample for our study is fairly small, it has
the advantage of having enrolled a relatively homogenous group
with regard to cancer characteristics, treatment, and follow-up,
thereby minimizing the effect of these critical confounders on
outcomes relevant to metastatic colorectal cancer.
Table 1. Characteristics of Study Population.
Characteristics N = 524 n (%)
Median Age (range) 61 (26–85)
Age ,50 86 (17)
50–65 255 (49)
.65 179 (34)
Sex Male 309 (59)
Female 215 (41)
Race White 450 (87)
Black 38 (7)
Other 31 (6)
ECOG Performance Status 0–1 500 (95)
2 24 (5)
doi:10.1371/journal.pone.0094727.t001
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Genome-wide association studies conducted in large patient
cohorts with clinical annotation have identified multiple common
polymorphisms that confer a small excess risk of developing
colorectal cancer. These SNPs help explain the heritability of
colorectal cancer beyond the uncommon high penetrance
mutations responsible for Lynch and Familial Adenomatous
Polyposis syndromes. Our study was underpowered to find small
effects of the candidate SNPs on survival, but as prognostic
markers with no more than minimal effect sizes are of little clinical
value, we believe these results support the notion that these
polymorphisms do not warrant further investigation as prognostic
markers in advanced colorectal cancer.
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